Payment overview · 2025
General Payments
$2,257.14
38 reported records · 17 companies
Healthcare provider profile · identity verified
Steven Kamara, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1275640336
Verified facts
What the public records show
CMS Open Payments records show Steven Kamara, M.D. received $2,257.14 in general payments during 2025 across 38 reported records.
Amgen Inc. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $470.93 | 20.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $375.62 | 16.6% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $264.72 | 11.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $243.51 | 10.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $183.79 | 8.1% | 3 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $166.88 | 7.4% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $130.86 | 5.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $98.17 | 4.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.63 | 2.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $54.50 | 2.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.59 | 1.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.58 | 1.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $31.09 | 1.4% | 2 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $29.20 | 1.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.48 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.04 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $24.55 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,257.14 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $267.00 | 4 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $264.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $213.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $185.86 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $185.86 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $183.79 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $166.88 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $140.04 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $130.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $108.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.63 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.63 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $54.50 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.59 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.28 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.62 | 2 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $26.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 197 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 64 |
| Ozempic | Semaglutide | 197 | 30 |
| Metformin Hcl | Metformin Hcl | 155 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 37 |
| Losartan Potassium | Losartan Potassium | 121 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 25 |
| Eliquis | Apixaban | 101 | 25 |
| Omeprazole | Omeprazole | 97 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 21 |
| Gabapentin | Gabapentin | 87 | 30 |
| Jardiance | Empagliflozin | 87 | 20 |
| Furosemide | Furosemide | 84 | 28 |
| Famotidine | Famotidine | 83 | 22 |
| Azithromycin | Azithromycin | 81 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 24 |
| Trazodone Hcl | Trazodone Hcl | 79 | 17 |
| Meloxicam | Meloxicam | 77 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 22 |
| Vascepa | Icosapent Ethyl | 74 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 18 |
| Mirtazapine | Mirtazapine | 73 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 20 |
| Simvastatin | Simvastatin | 66 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 13 |
| Tramadol Hcl | Tramadol Hcl | 60 | 22 |
| Montelukast Sodium | Montelukast Sodium | 55 | 12 |
| Lisinopril | Lisinopril | 53 | 15 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Linzess | Linaclotide | 46 | suppressed |
| Telmisartan | Telmisartan | 45 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Lactulose | Lactulose | 42 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 13 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | 15 |
| Cephalexin | Cephalexin | 38 | 32 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 20 |
| Alprazolam | Alprazolam | 37 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 14 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 15 |
| Prednisone | Prednisone | 35 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 12 |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 13 |
| Clonidine Hcl | Clonidine Hcl | 29 | 15 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 22 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | 11 |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | 11 |
| Risperidone | Risperidone | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,257.14 · 38 records | Amgen Inc. | AIRSUPRA, Attruby, BREZTRI, CAPLYTA, EVENITY, FFRct, Fibroscan, Korlym, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PYRUKYND, REPATHA, Rybelsus, Tresiba, VOQUEZNA, Wegovy, Yeztugo, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error